|
Mar 10
|
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
|
|
Mar 3
|
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
|
|
Feb 27
|
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
|
|
Feb 26
|
N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers
|
|
Feb 18
|
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
|
|
Jan 2
|
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval
|
|
Dec 31
|
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
|
|
Oct 1
|
SciSparc receives FDA approval for trial for Tourette syndrome therapy
|
|
Sep 30
|
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
|
|
Aug 29
|
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
|
|
Aug 28
|
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
|
|
Aug 26
|
SciSparc secures final approval in Israel to start Tourette’s Syndrome trial
|
|
Aug 26
|
SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial
|
|
Mar 21
|
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
|
|
Mar 18
|
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
|
|
Mar 14
|
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
|
|
Jan 29
|
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
|
|
Jan 24
|
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
|
|
Dec 7
|
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
|
|
Dec 1
|
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
|